Greater China News
Chinese Biopharma Firm WuXi XDC Climbs 36% on Debut in Hong Kong
A Chinese maker of drugs used in cancer treatments surged in Hong Kong after an initial public offering priced at the top of a marketed range, a rare case of strong demand for a listing in the financial hub of the year.
Hostility toward the U.S. in China has dropped sharply, new poll shows
Attitudes in China have become friendlier to the U.S. this year, according to a new survey from Morning Consult. One factor could be the slowdown in China's economy.
CASI Pharmaceuticals Announces Market Approval of CNCT19 by China NMPA
CASI Pharmaceuticals Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, is thrilled to announce a major milestone in its partnership with Juventas Cell Therapy Ltd. (Juventas). The China National Medical Products Administration (NMPA) has granted market approval for Juventas' investigational cell therapy, Inaticabtagene Autoleucel (CNCT 19), for the treatment of relapsed and refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) in China.
基石药业对外战略合作再下一城 携手艾力斯共同开发普吉华®中国市场 | 会员动态
根据协议，基石药业将获得首付款和后续的研发里程碑付款，并将继续获得普吉华®在中国大陆的销售收入，艾力斯将从基石药业收取服务费。这是基石药业继与三生制药达成Nofazinlimab（抗PD-1单抗）在中国大陆地区战略合作和独家许可协议后，本月内达成的第二起战略合作。
Eccogene Enters Exclusive License Agreement With AstraZeneca to Develop and Commercialize Small Molecule GLP-1 Receptor Agonist ECC5004 for Cardiometabolic Diseases
ccogene will receive initial upfront payment of $185 million. Eccogene is also eligible to receive up to $1.825 billion in future clinical, regulatory, and commercial milestones, as well as royalty payments.
Xi Jinping expected to speak at dinner for US business executives while in San Francisco for Apec
Bloomberg reported on Tuesday that Chinese President Xi Jinping was the headliner.
Axios: “Foreign investment in China goes negative for first time in decades”
by Matt Phillips, Axios Markets “Foreign investment into China turned negative for the first time on record in the third quarter. Why it matters: The outflow of foreign ... Read more
Biotheus Enters Into Strategic Partnership with BioNTech to Develop and Commercialize Bispecific Antibody Candidate Targeting PD-L1 and VEGF in Multiple Solid Tumor Indications
Biotheus Inc. ("Biotheus"), a clinical-stage biotech company dedicated to the discovery and development of biologics for oncology and inflammatory diseases, today announced that the company has entered into an exclusive global license and collaboration agreement under which BioNTech will be developing, manufacturing and commercializing PM8002 globally ex-Greater China, whereas Biotheus retains the rights to exploit PM8002 in Greater China.
Biotheus Announces Strategic Research Collaboration and Worldwide License Agreement with BioNTech
Biotheus Inc. ("Biotheus"), a clinical-stage biotech company dedicated to the discovery and development of biologics for oncology and inflammatory diseases, announced today that it has entered into a strategic research collaboration, option and worldwide license agreement with BioNTech SE ("BioNTech"), a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases.
Genexine and KGbio received the first market approval for novel long-acting Erythropoietin, Efepoetin alfa, from The Indonesian Food and Drug Authority (BPOM)
This milestone marks the first market approval for a drug originating from Genexine's research and development with KGbio.
